Loading...
XSHE
300233
Market cap873mUSD
Dec 05, Last price  
16.28CNY
1D
0.56%
1Q
-16.34%
Jan 2017
-33.20%
IPO
60.95%
Name

Shandong Jincheng Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
XSHE:300233 chart
P/E
31.39
P/S
1.83
EPS
0.52
Div Yield, %
1.84%
Shrs. gr., 5y
-0.60%
Rev. gr., 5y
3.83%
Revenues
3.37b
-4.66%
569,928,918584,608,999759,384,949788,420,535799,331,826908,713,1181,050,829,9731,178,560,3001,420,385,0192,788,037,1003,007,968,0492,794,819,3322,961,935,8343,138,454,2803,505,716,9623,538,312,4593,373,387,000
Net income
197m
+12.63%
53,666,15781,347,792104,624,06655,991,12841,610,64364,596,722108,700,716170,977,251159,390,211286,304,084263,863,408203,285,1860107,984,095273,365,308174,709,358196,781,000
CFO
297m
-55.34%
30,230,061105,624,585108,674,38862,690,63686,605,84993,921,980219,455,483207,917,945241,482,126151,829,060352,196,534577,983,378546,126,321437,185,450255,626,529664,075,132296,586,000
Dividend
Sep 20, 20240.1 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shandong Jincheng Pharmaceutical Group Co., Ltd, together with its subsidiaries, researches and develops, produces, markets, and sells Cephalosporin intermediates in China and internationally. The company offers active pharmaceutical ingredients, biopharmaceuticals, medical intermediates, fine chemicals, finished dosages, and pharmaceutical products. It also provides animal nutrition and health care, as well as CMO and CDMO services. The company was founded in 2004 and is based in Zibo, China.
IPO date
Jun 22, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT